Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06903312 | Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.(ITALIC-RCC) | recruiting | Phase 4 | 409 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07046182 | Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight | active not recruiting | Phase 4 | 34 | Zhengzhou UniversityOTHER | 1 |
| Jul 1, 2025 |
| clinicaltrials |
| NCT06173466 | Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone | completed | Phase 4 | 96 | Zhejiang Cancer HospitalOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07034859 | Cabergoline in the Management of Nonfunctioning Pituitary Adenoma | enrolling by invitation | Phase 4 | 30 | National Taiwan University HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04489888 | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | completed | Phase 4 | 101 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Jun 19, 2025 | clinicaltrials |
| NCT07020468 | Neoadjuvant Therapy (NALIRIFOX) for Locally Advanced Colon and Upper Rectal Cancer(HOPE) | active not recruiting | Phase 4 | 57 | Affiliated Cancer Hospital of Shantou University Medical CollegeOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | recruiting | Phase 4 | 59 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04362072 | Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer | completed | Phase 4 | 71 | PfizerINDUSTRY | 7 | Jun 11, 2025 | clinicaltrials |
| NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 4 | 45 | Beijing GoBroad HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05822817 | Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery | completed | Phase 4 | 252 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07004335 | Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study | not yet recruiting | Phase 4 | 40 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT07001709 | Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)(ENABLE) | recruiting | Phase 4 | 29 | Deventer ZiekenhuisOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05805436 | Preop Laxatives in Robotic Urologic Surgery | recruiting | Phase 4 | 240 | Chad R. TracyOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03190330 | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | completed | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT04042376 | A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) | completed | Phase 4 | 17 | Janssen Research & Development, LLCINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT01673984 | GP Extended Action Triptorelin(GREAT) | terminated | Phase 4 | 27 | IpsenINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT05333328 | OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk(INTERSTELLAR) | recruiting | Phase 4 | 418 | Gangnam Severance HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT04347122 | Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction | terminated | Phase 4 | 12 | University of Kansas Medical CenterOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | terminated | Phase 4 | 1 | Brian Anderson, MDOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03289741 | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | completed | Phase 4 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06090994 | Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy | recruiting | Phase 4 | 756 | Fudan UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT01490892 | Quantitative Subharmonic Breast Imaging | completed | Phase 4 | 219 | Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT03909646 | Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease(BOWTIE) | completed | Phase 4 | 250 | Maastricht University Medical CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT02047994 | Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality(GISTAR) | recruiting | Phase 4 | 30,000 | International Agency for Research on CancerOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06956092 | Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma(Glofitamab) | not yet recruiting | Phase 4 | 40 | Zhengzhou UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05071482 | Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL | terminated | Phase 4 | 39 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06834386 | Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06935708 | Intrathecal Morphine Versus Epidural Analgesia for Open Colon Surgery | recruiting | Phase 4 | 98 | Meri MircetaOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06931808 | Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer | enrolling by invitation | Phase 4 | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03500133 | Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.(LHGALOP2017) | recruiting | Phase 4 | 500 | Hospital JP GarrahanOTHER_GOV | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06923176 | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment(BRCSRRRHCCART) | not yet recruiting | Phase 4 | 704 | Zhiyun YangOTHER | 0 | Apr 11, 2025 | clinicaltrials |
| NCT05900908 | Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy(PATHWAyS) | withdrawn | Phase 4 | 0 | GT Medical Technologies, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06920810 | Viscum Album for TNBC on Adjuvant Pembrolizumab(TNBNOBA) | recruiting | Phase 4 | 40 | Ilsan Cha hospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06918054 | Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia | recruiting | Phase 4 | 42 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06918080 | Hepatoprotective Measures for Children at High Risk of NAFLD | active not recruiting | Phase 4 | 200 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06779318 | Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis | not yet recruiting | Phase 4 | 464 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | completed | Phase 4 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05551299 | Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy(CARP) | recruiting | Phase 4 | 258 | University of LeipzigOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT04781959 | A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy | completed | Phase 4 | 233 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03164980 | QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer(COMPASS) | terminated | Phase 4 | 89 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06881563 | Intrathecal Morphine Versus Epidural Analgesia for Laparoscopic Colon Surgery | not yet recruiting | Phase 4 | 98 | Meri MircetaOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06879691 | A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 4 | 171 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT00866684 | Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol(PROSKIN) | terminated | Phase 4 | 44 | Charite University, Berlin, GermanyOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05465031 | Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) | recruiting | Phase 4 | 600 | Silesian Centre for Heart DiseasesOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06871787 | Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery(INOCA) | not yet recruiting | Phase 4 | 50 | Istanbul UniversityOTHER | 1 | Mar 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 3, 2025source: clinicaltrials